Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Galluzzi

Showing results (21-30 of 599) with videos related to

Pageof 60
Sort By:
Oncoimmunology|July 4, 2015
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question markGuido Kroemer, Lorenzo Galluzzi
Oncoimmunology|July 9, 2015
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphomaGuido Kroemer, Lorenzo Galluzzi
Journal of Biotechnology|August 8, 2006
Intracellular redox equilibrium and growth phase affect the performance of luciferase-based biosensorsLorenzo Galluzzi, Matti Karp
Oncoimmunology|October 24, 2014
Novel insights into the mechanism of action of lenalidomideMichaela Semeraro, Lorenzo Galluzzi
Oncotarget|November 18, 2015
Defective autophagy gets to the brainLorenzo Galluzzi, Guido Kroemer
Oncoimmunology|November 18, 2017
Blinatumomab bridges the gap between leukemia and immunityTakahiro Yamazaki, Lorenzo Galluzzi
Oncoimmunology|December 7, 2017
CARs on a highway with roadblocksLorenzo Galluzzi, Peter Martin
Cell|December 27, 2008
Necroptosis: a specialized pathway of programmed necrosisLorenzo Galluzzi, Guido Kroemer
Oncoimmunology|June 5, 2013
Cancer immunotherapy turns viralLorenzo Galluzzi, Enrico Lugli
Oncotarget|December 16, 2016
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumorsGuido Kroemer, Lorenzo Galluzzi
Pageof 60

Showing results (21-30 of 599) with videos related to

Sort By:
Pageof 60
Oncoimmunology|July 4, 2015
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question markGuido Kroemer, Lorenzo Galluzzi
Oncoimmunology|July 9, 2015
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphomaGuido Kroemer, Lorenzo Galluzzi
Journal of Biotechnology|August 8, 2006
Intracellular redox equilibrium and growth phase affect the performance of luciferase-based biosensorsLorenzo Galluzzi, Matti Karp
Oncoimmunology|October 24, 2014
Novel insights into the mechanism of action of lenalidomideMichaela Semeraro, Lorenzo Galluzzi
Oncotarget|November 18, 2015
Defective autophagy gets to the brainLorenzo Galluzzi, Guido Kroemer
Oncoimmunology|November 18, 2017
Blinatumomab bridges the gap between leukemia and immunityTakahiro Yamazaki, Lorenzo Galluzzi
Oncoimmunology|December 7, 2017
CARs on a highway with roadblocksLorenzo Galluzzi, Peter Martin
Cell|December 27, 2008
Necroptosis: a specialized pathway of programmed necrosisLorenzo Galluzzi, Guido Kroemer
Oncoimmunology|June 5, 2013
Cancer immunotherapy turns viralLorenzo Galluzzi, Enrico Lugli
Oncotarget|December 16, 2016
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumorsGuido Kroemer, Lorenzo Galluzzi
Pageof 60